Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The 42nd Annual General Meeting of Kapil Cotex Limited (now being renamed Skybiotech Healthcare Limited, BSE Scrip: 512036) was held on September 25, 2025, and all 9 resolutions were passed with near-unanimous approval (over 99.99% in favor). Total paid-up equity shares stand at 19,15,000, with promoter group holding 12,15,575 shares (~63.5%). Key approvals include: adoption of audited standalone and consolidated financial statements for FY25, re-appointment of Mrs. Poonam Rathi as director (retiring by rotation), appointment of a new non-executive independent director (Mr. Vijay Chitlange), appointment of SM Dhumal & Associates as Secretarial Auditors, alteration of the main object clause of the MoA, change of company name to Skybiotech Healthcare Limited, increase in authorized share capital, and ratification of the acquisition of Skybiotech Life Sciences Private Limited. Public non-institutional participation was modest, with only about 17.89% of public shares being voted.
All resolutions cleared without controversy, so no immediate share-price shock is expected. However, the simultaneous name change, MoA alteration, and authorized capital hike suggest the company is pivoting from textiles into the healthcare/biotech space, which investors should monitor for follow-up fundraising or business updates.